Puma Biotechnology, Inc. $PBYI Shares Bought by Metis Global Partners LLC

Metis Global Partners LLC raised its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 30.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 55,798 shares of the biopharmaceutical company’s stock after purchasing an additional 13,040 shares during the quarter. Metis Global Partners LLC’s holdings in Puma Biotechnology were worth $191,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PBYI. Royal Bank of Canada lifted its holdings in shares of Puma Biotechnology by 3.8% in the 1st quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 3,117 shares during the period. C2C Wealth Management LLC grew its holdings in Puma Biotechnology by 36.1% during the second quarter. C2C Wealth Management LLC now owns 20,620 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 5,470 shares during the period. CWM LLC raised its position in Puma Biotechnology by 214.1% during the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 6,450 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Puma Biotechnology by 2.7% in the first quarter. Bank of New York Mellon Corp now owns 340,886 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 9,033 shares during the period. Finally, Savant Capital LLC purchased a new stake in Puma Biotechnology in the 2nd quarter worth approximately $44,000. 61.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Puma Biotechnology

In related news, Director Michael Patrick Miller sold 20,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $4.86, for a total transaction of $97,200.00. Following the completion of the transaction, the director owned 54,000 shares in the company, valued at $262,440. This represents a 27.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 23.30% of the stock is currently owned by company insiders.

Puma Biotechnology Trading Down 0.8%

Shares of NASDAQ:PBYI opened at $4.95 on Friday. The business’s 50 day moving average price is $5.01 and its 200-day moving average price is $4.16. Puma Biotechnology, Inc. has a 1 year low of $2.32 and a 1 year high of $6.12. The firm has a market capitalization of $249.34 million, a price-to-earnings ratio of 5.05 and a beta of 1.35. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.09 by $0.12. The company had revenue of $54.48 million during the quarter, compared to analyst estimates of $51.00 million. Puma Biotechnology had a net margin of 20.38% and a return on equity of 53.15%. Puma Biotechnology has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PBYI has been the subject of several recent research reports. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings lowered shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Puma Biotechnology has an average rating of “Moderate Buy” and an average target price of $7.00.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.